NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Hepatitis C, Chronic

Interventions: Pegylated Interferon Alfa-2a, Ribavirin

Countries: Georgia

This prospective observational study will investigate predictive values of virological response in pegylated interferon alfa-2a (Pegasys)/ribavirin (Copegus) treatment-naive participants with chronic hepatitis C. Participants will be treated with pegylated interferon alfa-2a and ribavirin as prescribed by the physician. Data will be collected for a maximum of 96 weeks.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

\- Diagnosis of chronic hepatitis C infection

Exclusion Criteria:

* Co-infection with human immunodeficiency virus (HIV) and/or hepatitis B
* Participants previously treated with pegylated interferon alfa-2a/ribavirin
* Participation in another clinical study within 30 days prior to study start of ML25544

Locations (3)

Tbilisi, Georgia
Tbilisi, Georgia
Tbilisi, Georgia